ANDA 76162, held by Watson Labs Teva. Carboplatin.
As of Nov 15, 2026, ANDA 76162 (Carboplatin), held by Watson Labs Teva, was first approved by FDA on Oct 14, 2004, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 14, 2004 | Original application | Approved |
| Carboplatin50MG/VIAL · injectable;injection | Carboplatin | Discontinued |
| Carboplatin150MG/VIAL · injectable;injection | Carboplatin | Discontinued |
| Carboplatin450MG/VIAL · injectable;injection | Carboplatin | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
